Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
U2AF1 mutation
i
Other names:
U2AF1, U2 Small Nuclear RNA Auxiliary Factor 1, U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein, U2 SnRNP Auxiliary Factor Small Subunit, Splicing Factor U2AF 35 KDa Subunit, U2AFBP, U2AF35, U2 Small Nuclear Ribonucleoprotein Auxillary Factor, 35-KD Subunit, U2(RNU2) Small Nuclear RNA Auxiliary Factor 1, U2 Small Nuclear RNA Auxillary Factor 1, Splicing Factor U2AF 35kDa Subunit, U2 Auxiliary Factor 35 KDa Subunit, RNU2AF1, FP793, RN
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
7307
Related biomarkers:
Mutation
‹
NRAS mutation + U2AF1 mutation (1)
U2AF1 S34F (1)
NRAS mutation + U2AF1 mutation (1)
U2AF1 S34F (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
U2AF1 mutation
Acute Myelogenous Leukemia
U2AF1 mutation
Acute Myelogenous Leukemia
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
U2AF1 mutation
Myelodysplastic Syndrome
U2AF1 mutation
Myelodysplastic Syndrome
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
U2AF1 mutation
Acute Myelogenous Leukemia
U2AF1 mutation
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Resistant: C3 – Early Trials
cytarabine / daunorubicin liposomal formulation
Resistant
:
C3
cytarabine/daunorubicin liposomal formulation
Resistant: C3 – Early Trials
cytarabine / daunorubicin liposomal formulation
Resistant
:
C3
U2AF1 mutation
Acute Myelogenous Leukemia
U2AF1 mutation
Acute Myelogenous Leukemia
cytarabine
Resistant: C3 – Early Trials
cytarabine
Resistant
:
C3
cytarabine
Resistant: C3 – Early Trials
cytarabine
Resistant
:
C3
U2AF1 mutation
Myelodysplastic Syndrome
U2AF1 mutation
Myelodysplastic Syndrome
azacitidine
Resistant: C3 – Early Trials
azacitidine
Resistant
:
C3
azacitidine
Resistant: C3 – Early Trials
azacitidine
Resistant
:
C3
U2AF1 mutation
Myelodysplastic Syndrome
U2AF1 mutation
Myelodysplastic Syndrome
decitabine
Resistant: C3 – Early Trials
decitabine
Resistant
:
C3
decitabine
Resistant: C3 – Early Trials
decitabine
Resistant
:
C3
U2AF1 mutation
Acute Myelogenous Leukemia
U2AF1 mutation
Acute Myelogenous Leukemia
venetoclax + ABBV 075
Sensitive: C3 – Early Trials
venetoclax + ABBV 075
Sensitive
:
C3
venetoclax + ABBV 075
Sensitive: C3 – Early Trials
venetoclax + ABBV 075
Sensitive
:
C3
U2AF1 mutation
Acute Myelogenous Leukemia
U2AF1 mutation
Acute Myelogenous Leukemia
HPB-092
Sensitive: D – Preclinical
HPB-092
Sensitive
:
D
HPB-092
Sensitive: D – Preclinical
HPB-092
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login